ArticleOncogenesis2018
Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways.
Article in Oncogenesis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- MUC15 Ectodomain Architecture Regulates Integrin Clustering to Control Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mucus and mucin: changes in the mucus barrier in disease states.Tissue barriers · 2025Review
- MUC15 acts as a tumor suppressor gene which correlates with prognosis and immune infiltration in esophageal squamous cell carcinoma.International journal of medical sciences · 2025Article
- Traditional Chinese Medicine Treatment of Thyroid Cancer: A Review.International journal of general medicine · 2025Review
- How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling.International journal of molecular sciences · 2024Review
- Effects of BYL-719 (alpelisib) on human breast cancer stem cells to overcome drug resistance in human breast cancer.Frontiers in pharmacology · 2024Article
- View from the Biological Property: Insight into the Functional Diversity and Complexity of the Gut Mucus.International journal of molecular sciences · 2023Review
- MUC15 is an independent prognostic factor that promotes metastases of MYCN non-amplified neuroblastoma.Journal of Cancer · 2023Article
- The covert symphony: cellular and molecular accomplices in breast cancer metastasis.Frontiers in cell and developmental biology · 2023Review
- LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma.Frontiers in immunology · 2023Article
- LPAR5 confers radioresistance to cancer cells associated with EMT activation via the ERK/Snail pathway.Journal of translational medicine · 2022Article
- Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.Cell death & disease · 2022Article
- LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway.Bioengineered · 2021Article
- High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.Journal of the mechanics and physics of solids · 2020Article
- Integrated bioinformatics analysis to screen hub genes in the lymph node metastasis of thyroid cancer.Oncology letters · 2020Article
- Establishment of a 5-gene risk model related to regulatory T cells for predicting gastric cancer prognosis.Cancer cell international · 2020Article
- Systematical Analysis of the Cancer Genome Atlas Database RevealsFrontiers in molecular biosciences · 2020Article
- Nuclear FAM289-Galectin-1 interaction controls FAM289-mediated tumor promotion in malignant glioma.Journal of experimental & clinical cancer research : CR · 2019Article
- Single-Gene Deletions Contributing to Loss of Heterozygosity inG3 (Bethesda, Md.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is the fifth most common cancer diagnosed in women worldwide. Notwithstanding advancements in the prognosis and treatment of thyroid cancer, 10-20% of thyroid cancer patients develops chemotherapeutic resistance and experience relapse. According to previous reports and TCGA database, MUC15 (MUCIN 15) upregulation is highly correlated with thyroid cancer progression. However, the role of MUC15 in tumor progression and metastasis is unclear. This study aimed to investigate factors mediating cancer stemness in thyroid cancer. MUC15 plays an important role in sphere formation, as an evident from the expression of stemness markers including SOX2, KLF4, ALDH1A3, and IL6. Furthermore, ectopic expression of MUC15 activated extracellular signal-regulated kinase (ERK) signaling via G-protein-coupled receptor (GPCR)/cyclic AMP (cAMP) and integrin/focal adhesion kinase pathways. Interestingly, ectopic expression of MUC15 did not affect RAF/mitogen-activated protein kinase kinase (MEK)-mediated ERK activation. The present findings may provide novel insights into the development of diagnostic, prognostic, and therapeutic applications of MUC15 in thyroid cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.